1
项与 Anti-CD19 CAR-T cell therapy(Affiliated Hospital to Academy of Military Medical Sciences) 相关的临床试验Treatment of Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia by Chimeric Antigen Receptor (CAR)-Modified T Cells
Traditional standard treatments of B cell acute lymphoblastic leukemia is not perfect for fighting cancer. Many people do not respond to the standard treatments of ALL. One possible treatment is chimeric antigen receptor (CAR) modified T cell infusions. This study aims to evaluate the safety and efficacy of novel CARTs (targeting CD19) in the treatment of refractory or recurrent ALL.The investigators start Phase I study aimed to chemotherapy resistant or refractory acute lymphoblastic leukemia patients. The purpose of this study is to assess the safety and effectiveness of CAR-T cells in patients.
100 项与 Anti-CD19 CAR-T cell therapy(Affiliated Hospital to Academy of Military Medical Sciences) 相关的临床结果
100 项与 Anti-CD19 CAR-T cell therapy(Affiliated Hospital to Academy of Military Medical Sciences) 相关的转化医学
100 项与 Anti-CD19 CAR-T cell therapy(Affiliated Hospital to Academy of Military Medical Sciences) 相关的专利(医药)
100 项与 Anti-CD19 CAR-T cell therapy(Affiliated Hospital to Academy of Military Medical Sciences) 相关的药物交易